Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric risankizumab for moderate to severe Crohn's disease
2022-502050-14-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in Crohn's disease (4 arms), sponsored by AbbVie Inc. Planned start Jun 2024; status: authorised.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2022-502050-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502050-14-00.